This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AVXS AveXis (AVXS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About AveXis Stock (NASDAQ:AVXS) 30 days 90 days 365 days Advanced Chart Get AveXis alerts:Sign Up Key Stats Today's Range$217.83▼$217.8350-Day Range N/A52-Week Range$65.54▼$217.94Volume222 shsAverage Volume816,305 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAveXis, Inc., a clinical-stage gene therapy company, engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its initial product candidate is AVXS-101, a gene therapy product candidate that has completed Phase I clinical trial for the treatment of spinal muscular atrophy Type 1. The company also intends to identify, acquire, develop, and commercialize gene therapy product candidates for the treatment of other rare and life-threatening neurological genetic diseases. It has strategic collaboration and license agreements with Nationwide Children's Hospital; The Research Institute at Nationwide Children's Hospital; REGENXBIO Inc.; and Asklepios Biopharmaceutical, Inc. The company was formerly known as BioLife Cell Bank, Inc. and changed its name to AveXis, Inc. in January 2014. AveXis, Inc. was founded in 2010 and is headquartered in Bannockburn, Illinois.Read More… Receive AVXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AveXis and its competitors with MarketBeat's FREE daily newsletter. Email Address AVXS Stock News HeadlinesNovartis ‘focusing on high-end, innovative medicines,’ CEO saysMay 24, 2023 | finance.yahoo.comIonis Childhood Spine Disorder Drug Notches Pivotal Study Win, Triggers Biogen OptionJanuary 2, 2023 | thestreet.comTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.June 25 at 2:00 AM | Porter & Company (Ad)Google-backed gene therapy firm launches Morrisville manufacturing facility - The Business JournalsSeptember 21, 2022 | bizjournals.comRegenxbio Stock: A Transformative Year (NASDAQ:RGNX) - Seeking AlphaSeptember 15, 2022 | seekingalpha.comGenSight Biologics Strengthens Its Management Team to Support the Launch of LUMEVOQ® in Europe - Yahoo FinanceSeptember 12, 2022 | finance.yahoo.comREGENXBIO: Gene Therapy Pioneer Moving To Late-Stage Development (NASDAQ:RGNX) - Seeking AlphaAugust 29, 2022 | seekingalpha.comOnce high-flying Dallas biotech sees promising drug data amid growing financial pressure - The Dallas Morning NewsAugust 29, 2022 | dallasnews.comDSee More Headlines AVXS Stock Analysis - Frequently Asked Questions How were AveXis' earnings last quarter? AveXis, Inc. (NASDAQ:AVXS) released its quarterly earnings data on Wednesday, May, 9th. The company reported ($6.20) EPS for the quarter, missing the consensus estimate of ($3.32) by $2.88. When did AveXis IPO? AveXis (AVXS) raised $86 million in an initial public offering (IPO) on Thursday, February 11th 2016. The company issued 4,300,000 shares at $19.00-$21.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and BMO Capital Markets and Chardan were co-managers. What other stocks do shareholders of AveXis own? Based on aggregate information from My MarketBeat watchlists, some other companies that AveXis investors own include REGENXBIO (RGNX), bluebird bio (BLUE), Bristol Myers Squibb (BMY), Exelixis (EXEL), Mallinckrodt (MNK), AbbVie (ABBV) and BioLife Solutions (BLFS). Company Calendar Last Earnings5/09/2018Today6/25/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:AVXS CIK1652923 Webwww.avexis.com Phone847-572-8280FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:AVXS) was last updated on 6/25/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AveXis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AveXis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.